Highlights
- 1
Publications
26 publications
Funding
7 grantsView NIH portfolio on RePORTER ↗
Active
1 grant- Co-IR61HL151355-01Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's AtaxiaNational Heart, Lung, and Blood Institute · 2020–2027
Completed grants (6)
- Co-IU01DA048524-01Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine AddictsNational Institute on Drug Abuse · 2019–2024
- Co-IADDF 171089-01Phase I Study of an AAVrh.10-Mediated Apolipoprotein E2 Gene Delivery to the CNS for the Treatment of Alzheimer's Disease in E4 HomozygotesAlzheimer's Drug Discovery Foundation · 2018–2023
- MPIFARA 194201-02Corneal Confocal Microscopy Quantitative Imaging of Corneal Nerves as a Biomarker of Neurologic Disease in Friedreich's AtaxiaFriedreich's Ataxia Research Alliance · 2019–2021
- Co-IFARA 194278-01Gene Therapy for Cardiac Manifestations of Friedreich's AtaxiaFriedreich's Ataxia Research Alliance · 2019–2021
- PIR03AI122040-02Gene Therapy for the Treatment of Hereditary AngioedemaNational Institute of Allergy and Infectious Diseases · 2016–2019
- PIPBF 170604-01Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy: A Gene Therapy ApproachParker B. Francis Foundation · 2015–2018Fellowship
News mentions
1 mentionView all WCM news ↗
- Innovative Imaging Technology Effectively Measures Disease Severity in Rare Neurodegenerative DisorderJanuary 15, 2019
A rapid, non-invasive eye exam that uses innovative imaging technology effectively measures the severity of disease in patients with a rare neurodegenerative disease called Friedrich ataxia, according to a study by Weill Cornell Medicine, Weill Cornell Medicine-Qatar and NewYork-Presbyterian researchers.